Allergy Therapeutics Achieves Key Milestone in Peanut Allergy Treatment Trial

The latest update is out from Allergy Therapeutics ( (GB:AGY) ).

Allergy Therapeutics announced that its Phase I/IIa PROTECT trial has successfully met its primary safety endpoint at the highest planned treatment dose. Preliminary safety data from 48 participants, including both peanut-allergic and healthy individuals, demonstrated that a 2000-fold increase in dose was safe and well tolerated. The trial’s results support the safety and efficacy of the VLP Peanut treatment, with preparations underway for a Phase IIb trial. This milestone reinforces the company’s confidence in its short-course approach and positions it well for further clinical development.

The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.

Spark’s Take on GB:AGY Stock

According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.

The stock score is primarily impacted by the company’s weak financial performance and valuation concerns, which are somewhat balanced by positive technical indicators and promising corporate events. The financial instability remains a significant risk, although recent product developments offer potential upside.

To see Spark’s full report on GB:AGY stock, click here.

More about Allergy Therapeutics

Allergy Therapeutics is a fully integrated commercial biotechnology company specializing in allergy immunotherapies. The company focuses on developing treatments for allergies, with a particular emphasis on peanut allergies, using innovative approaches such as VLP Peanut.

Average Trading Volume: 383,002

Technical Sentiment Signal: Buy

Current Market Cap: £657.1M

For a thorough assessment of AGY stock, go to TipRanks’ Stock Analysis page.